On April 22, 2024, ImmunityBio's Anktiva (N-803) plus BCG got FDA approval for BCG-unresponsive NMIBC with CIS, with/without papillary tumors.

Pathios Therapeutics Secures $25M in Initial Series B Funding Round to Propel Unique Immunotherapy Strategy into Clinical Trials.

Commonly used radioactive isotopes include 125I and 131I, which can undergo iodination reactions with the tyrosine residues in the antibody.

GV20 Therapeutics Reveals Partnership for Clinical Study to Test GV20-0251, an Innovative Antibody Targeting New Immune Checkpoint IGSF8, Together with KEYTRUDA® (pembrolizumab).

The Synapse Database for Translational Medicine is now live, come and experience it!

Results from the Phase 3 SELECT-GCA trial indicate that Upadacitinib (RINVOQ®) offers promising outcomes for individuals with Giant Cell Arteritis.

In the design process of shRNA (short hairpin RNA), the fragment length is an important consideration factor, as it can affect the efficiency and specificity of RNA interference (RNAi).

NMPA Greenlights IND Submission for Initial Clinical Trial Using HLX53 Anti-TIGIT Fc Fusion Protein in Conjunction with HANSIZHUANG and HANBEITAI for Early Treatment in Patients with Advanced or Metastatic Liver Cancer.

April 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Vertex Pharmaceuticals reports advancements in its suzetrigine pain treatment program. Suzetrigine, also known as VX-548, is an oral NaV1.8 inhibitor that could be the first new painkiller class for acute and neuropathic pain in two decades.

In the field of tumor treatment, antibody-drug conjugates (ADCs) have the potential to enhance the efficacy and specificity of cancer therapy by combining monoclonal antibodies with potent cytotoxic drugs.

4.15-4.21 Global Drug R&D Progress & Pharmaceutical Transaction Trends.